指南与共识泌尿生殖技术与安全PETMRCT

SNMMI/EANM/ACNM肾肿块分子影像表征操作标准/操作指南

SNMMI/EANM/ACNM Procedure Standard/Procedure Guideline on the Use of Molecular Imaging for Renal Mass Characterization.
指南 / 共识 · J Nucl Med · 2025-12-03

该指南由SNMMI、EANM和ACNM联合制定,针对肾肿块分子影像表征提出推荐方法。指南聚焦靶向碳酸酐酶IX的89Zr-girentuximab和线粒体显像剂99mTc-sestamibi两条路径,指出两者互补信息可改善风险分层,并提及新兴靶向示踪剂和人工智能影像生物标志物发现将支撑相关概念。

要点

  • 89Zr-girentuximab靶向碳酸酐酶IX,在透明细胞肾细胞癌高表达,其他肾肿瘤一般不表达。
  • 99mTc-sestamibi为亲脂性阳离子,在富线粒体肿瘤(如嗜酸细胞瘤等良性/惰性病变)中积聚,在多药耐药泵肿瘤(如透明细胞肾细胞癌)中不积聚。
  • 89Zr-girentuximab与99mTc-sestamibi的互补信息可提供改善的风险分层。

核心结论

  • 肾肿块解剖影像对组织学或肿瘤侵袭性的信息有限,分子影像可辅助不确定肾肿块的风险分层,可能有助于优化患者决策。

研究设计与样本

  • 该文件为SNMMI/EANM/ACNM操作标准/操作指南,制定机构为SNMMI、EANM和ACNM,方法为综合关键数据形成推荐方法,原文未报告证据分级。

关键影像表现/征象

  • 原文未报告具体影像征象。

诊断标准与关键数值

  • 靶向碳酸酐酶IX的89Zr-girentuximab在透明细胞肾细胞癌上过表达,其他肾肿瘤一般不表达。
  • 99mTc-sestamibi在富线粒体且带负电位点的肿瘤(如嗜酸细胞瘤及其他良性/惰性病变)中积聚,在多药耐药泵肿瘤(如透明细胞肾细胞癌)中不积聚。

临床应用与阅片要点

  • 原文推荐将89Zr-girentuximab与99mTc-sestamibi的互补信息用于改善肾肿块风险分层。
  • 原文提及新兴靶向放射性示踪剂和人工智能影像生物标志物发现等技术将支撑上述概念。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Anatomic imaging of renal masses provides limited information on the histology or likely aggressiveness of the tumor, leading to the use of invasive procedures such as renal mass biopsy or empiric partial or radical nephrectomy. Molecular imaging can assist in risk stratification of indeterminate renal masses, potentially contributing to optimal patient decision-making. Two primary approaches have been explored for renal mass molecular imaging. The first is the use of agents that target carbonic anhydrase IX (CAIX), a cell-surface protein that is over-expressed on clear cell renal cell carcinoma (ccRCC) and generally not expressed on other renal tumors. A recent phase III trial (ZIRCON) is widely believed to have laid the groundwork for United States Food and Drug Administration approval of the CAIX monoclonal antibody 89Zr-girentuximab. The second approach is the use of mitochondrial imaging agents, most notably 99mTc-sestamibi, which are lipophilic cations that accumulate in tumors with an abundance of mitochondria with negative charge potential (e.g., oncocytomas and other benign/indolent lesion) and do not accumulate in tumors with multidrug resistance pumps (e.g., ccRCC). The complementary information from 89Zr-girentuximab and 99mTc-sestamibi can provide improved risk stratification. Further, emerging new targeted radiotracers and techniques such as imaging biomarker discovery with artificial intelligence will bolster those concepts. In this manual, we synthesize key data into a recommended approach.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Rowe SP, Shuch BM, Ball MW, et al. SNMMI/EANM/ACNM Procedure Standard/Procedure Guideline on the Use of Molecular Imaging for Renal Mass Characterization. J Nucl Med. 2025. PMID: 41067863. doi:10.2967/jnumed.125.271332

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。